LGD-4033 and RAD-140 Interaction
LGD-4033 and RAD-140 have an interaction requiring monitoring for interaction with 90% confidence. Stacking LGD-4033 with RAD-140 compounds the suppression of the HPG axis and increases the risk of liver enzyme elevation and lipid disruption. While some users combine these two SARMs, the additive suppression makes post-cycle recovery significantly more difficult without proportional additional benefit. If this combination is used, a testosterone base and comprehensive blood work monitoring are strongly advised. Most experienced users recommend choosing one SARM per cycle rather than stacking. Both compounds affect the gonads and liver and heart, so monitoring these systems is recommended.
Compound Profiles
LGD-4033
Selective Androgen Receptor Modulator | Lean Mass
LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.
View full profileRAD-140
Selective Androgen Receptor Modulator | Investigational SARM
RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take LGD-4033 with RAD-140?
Yes, but with caution. Stacking LGD-4033 with RAD-140 compounds the suppression of the HPG axis and increases the risk of liver enzyme elevation and lipid disruption. While some users combine these two SARMs, the additive suppression makes post-cycle recovery significantly more difficult without proportional additional benefit. If this combination is used, a testosterone base and comprehensive blood work monitoring are strongly advised. Most experienced users recommend choosing one SARM per cycle rather than stacking. Regular monitoring is advised.
Is LGD-4033 and RAD-140 safe together?
Based on documented research, this combination is considered monitor. However, shared safety flags include: androgenic, blood pressure raising, carcinogenic risk, hepatotoxic, hpta suppressive, lipid disrupting. Monitor accordingly.
What are the interactions between LGD-4033 and RAD-140?
Stacking LGD-4033 with RAD-140 compounds the suppression of the HPG axis and increases the risk of liver enzyme elevation and lipid disruption. While some users combine these two SARMs, the additive suppression makes post-cycle recovery significantly more difficult without proportional additional benefit. If this combination is used, a testosterone base and comprehensive blood work monitoring are strongly advised. Most experienced users recommend choosing one SARM per cycle rather than stacking. This assessment has 90% confidence and is based on documented research data.
How should I time LGD-4033 and RAD-140?
LGD-4033 has a half-life of ~24-36 hours and RAD-140 has a half-life of ~60 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.